

# Worldwide Preclinical & Discovery Alliance for Small Molecule Protein Degraders to Treat Inflammation

## KT-474 Ubiquitin-Mediated Protein Degradation Targeting

### IRAK4 for Inflammation (7/20)

- \$150M upfront payment
- Kymera funds dev thru Phase I trials
- \$1B in dev/reg milestones for IRAK4
- \$480M dev/reg milestones for add'l target
- \$700M in sales milestones, of which \$400M is for IRAK4 compounds

**Kymera  
Therapeutics**

**Sanofi**

Kymera has option to fund 50% of US dev costs for equal US profit sharing & co-promotion rights

**High Single-digit  
to High Teen  
Royalties**

Sanofi has rights to one add'l target, subject to Kymera's co-co option

# Regional Phase III License of Pitolisant to Treat Narcolepsy in the US

## Wakix Pitolisant Histamine-H3 Receptor Antagonist for Narcolepsy (6/17)

Harmony Biosciences

- \$150M upfront payment
- Bioprojet pays all dev costs
- \$127M in dev/reg milestones 1<sup>st</sup>
- \$102M in dev/reg milestones add'l
- \$40M in sales milestones

Bioprojet

13% to \$200M  
15% to \$400M  
21% to \$600M  
24% > \$600M/yr\*

Bioprojet supplies at COGS plus CON %

\* Plus 3% Trademark royalty for 20 yrs from FCS

# Worldwide Discovery & Co-Co Alliance for mRNA Vaccines & Antibodies in Infectious Diseases

## Messenger RNA Technology for Prophylactic Vaccines & Antibodies to Infectious Diseases (7/20)

CureVac

Glaxo-SmithKline

- \$138M upfront & \$173M equity (€270M)
- GSK pays for first 2 programs; CureVac pays thru Ph I for add'l, with reimb by GSK after dev option exercise
- \$93M in dev/reg milestones/program
- \$117M in sales milestones/program
- \$369M in agg dev/reg milestones (€320M)
- \$438M in agg sales milestones (€380M)

CureVac distributes in Austria, Germany & Switzerland for low 30% transfer price

Single-digit To Low Teen Royalties

GSK has exclusive right to lipid nanoparticle (LNP) technology for its programs

# Worldwide Discovery & Co-Co Alliance for Small Molecules to Protein Targets

## DNA-encoded Library of Ubiquitin E3 Ligases to Degrade Chimeric Targeting Molecules(12/19)

Nurix

- \$55M upfront payment
- Nurix pays its research costs
- \$170M in extension/expansion fees
- \$1.125B in dev/reg milestones
- \$1.3B in sales milestones

Sanofi

Nurix may co-develop two targets at Clinical POC for 50% PS in US

Mid Single-digit  
To Low Teen  
Royalties

Three initial targets, & Sanofi may add 2 add'l

# Worldwide Discovery & Co-Development Alliance for Screening of Oncology Targets

## SNIPRx Synthetic Lethality Technology for CRISPR Screening of Targets (5/20)

Repare

- \$50M upfront payment
- \$15M warrant converted to eq @ IPO
- Repare pays dev costs thru validation
- \$176M in dev/reg milestones/target
- \$125M in sales milestones/target

Bristol-Myers

High Single-digit  
To Low Double-  
digit Royalties

ROFN to add'l Repare  
compounds

# Worldwide Discovery Alliance for Antibody-Oligonucleotide Compounds for up to 6 RNA Targets

AOC Antibody-Oligo Conjugates in Immunology (4/19)

Avidity  
Biosciences

- \$20M upfront payment
- \$15M loan, converted to equity at 80% of next financing price/share
- \$200M in dev/reg milestones/target
- \$205M in sales milestones/target

Lilly

Mid Single-digit  
to Low Double-  
digit Royalty

# Worldwide Phase I Co-Co Alliance for CAR-T Therapy to Treat Multiple Myeloma

## LCAR-B38M CAR-T to BCMA for Treatment of Multiple Myeloma (12/17)

Legend Biotech

- \$350M upfront payment
- Parties share all clinical costs
- \$215M in dev milestones
- \$800M in regulatory milestones
- \$125M in manufacturing milestones
- \$210M in sales milestones

Janssen

\* Legend prices & books sales in Greater China and has 70/30 profit split

50/50 PS  
Ex-Greater China\*

Janssen prices & books sales in ROW

# Worldwide Preclinical Alliance for Oral Compounds to Treat Liver Fibrosis

## PLN-1474 AlphaV-Beta1 Integrin Inhibitor for Treatment of NASH (10/19)

Pliant  
Therapeutics

- \$50M upfront payment
- \$20M Ser C equity, plus \$10M at IPO
- \$19.6M R&D funding thru Phase I
- \$416M in agg milestones

Novartis

Mid-Single Digit  
To Low Teen  
Royalties

Novartis has rights to up to three add'l targets



# Worldwide Phase I License of Compounds to Treat Cancers with Altered Notch Genes

## AL101 & AL102 Gamma Secretase Inhibitors for Treatment of Cancer (11/17)

Bristol-Myers  
Squibb

- \$6M upfront payment
- \$7.3M of Ayala equity (8% OS)
  - Ayala pays all dev costs
- \$95M in dev/reg milestones 1<sup>st</sup>
- \$47M in dev/reg milestones add'l
  - \$50M in sales milestones

Ayala  
Pharmaceuticals

High Single-Digit  
To Mid-Teen  
Royalty


# Worldwide Discovery Alliance for Ligand Trap Technology to Treat Metabolic Diseases

## Ligand Trap Platform for Treatment of Diabetes, Obesity, NASH & Cachexia (12/17)

Keros  
Therapeutics

- \$16M upfront payment
- \$4M in R&D payments over two years
  - Novo pays all dev costs
- \$96M in dev/reg milestones 1<sup>st</sup>
- \$225.5M in dev/reg milestones add'l
- \$70M in sales milestones

Novo Nordisk



Mid Single-Digit  
Royalty

# Worldwide Preclinical Co-Co Alliance for Inhibition of Cell Growth Signaling to Treat Cancer

## RMC-4630 SHP2 Inhibitor for Treatment of Non-Small Lung Cancer (6/18)

- \$50M upfront payment
- RevMed pays 20% of R&D for two yrs
- Sanofi pays all dev costs
- \$520M in dev/reg milestones

Revolution Medicines

Sanofi

RevMed has option to co-promote CON % of US Details

US 50/50 PS;  
High Single to Mid-Teen  
Royalty in ROW

Sanofi has ROFN for any SHP1-SHP2 Dual Inhibitors

# Worldwide Phase I License Option for Topical Compound to Treat Dermatological Disorders

## ARQ-252 JAK1 Inhibitor for Treatment of Eczema (1/18)

Jiangsu  
Hengrui

- \$0.4M upfront for 18 month option
- \$1.5M on option exercise (12/19)
  - Arcutis pays all dev costs
- \$20.5M in dev/reg milestones
- \$200M in sales milestones

Arcutis  
Biotherapeutics

Mid-Single Digit  
to Sub-Teen  
Royalty